An observational study in Stage 1 Hypertension, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. — 1 open to participants now, 3 under way, none of them phase 3. Hypertension · Daewoong Pharmaceutical Co. LTD..
Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 15th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →1 of the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD. is open now, in 1 country.
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12,000 is above the median of 352 across 1,166 observational studies indexed under Hypertension.
Median enrollment 128 across the 10 interventional studies, 5,450 across the 5 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Hypertension by Daewoong Pharmaceutical Co. LTD., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.
This is a prospective, multicenter, observational study designed to evaluate the effectiveness of Olmetec® (olmesartan medoxomil) or Olmetec Plus® (olmesartan medoxomil/hydrochlorothiazide) on nocturnal blood pressure control in Korean patients with stage 1 hypertension.
In routine clinical practice, patients diagnosed with stage 1 hypertension and newly prescribed Olmetec® or Olmetec Plus® according to the approved label and the physician's clinical judgment will be enrolled and followed prospectively. No additional intervention beyond standard medical care will be applied.
Ambulatory blood pressure monitoring (ABPM) will be used to assess 24-hour blood pressure profiles, including nocturnal blood pressure, daytime blood pressure, and blood pressure variability. Measurements will be performed at baseline and after treatment to evaluate changes over time.
The primary objective of this study is to assess the change in mean systolic blood pressure from baseline to 12 weeks (up to 20 weeks). Secondary objectives include evaluation of diastolic blood pressure, nocturnal blood pressure, blood pressure variability, responder rate, and changes in dipping patterns. Safety will be assessed by monitoring adverse events during the study period.
This study aims to generate real-world evidence on the effectiveness and safety of Olmetec-based therapy in controlling nocturnal blood pressure and improving blood pressure variability in patients with stage 1 hypertension.
Patients with stage 1 hypertension in Korea who are newly prescribed Olmetec® or Olmetec Plus® according to routine clinical practice. Eligible patients are adults who meet the inclusion and exclusion criteria and are able to undergo ambulatory blood pressure monitoring (ABPM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with stage 1 hypertension who are prescribed Olmetec® or Olmetec Plus® as part of routine clinical practice will be included. Patients will be followed prospectively to assess changes in nocturnal blood pressure and blood pressure variability using ambulatory blood pressure monitoring (ABPM). No intervention beyond standard clinical care will be applied.
Change in mean 24-hour systolic blood pressure
Change in mean 24-hour systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM) from baseline to 12 weeks (up to 20 weeks).
Time frame: Baseline to 12 weeks (up to 20 weeks)
Change in clinic systolic and diastolic blood pressure
Change in clinic systolic and diastolic blood pressure from baseline.
Time frame: Baseline to 12 weeks (up to 20 weeks)
Responder rate
Proportion of patients achieving systolic blood pressure \<140 mmHg or a reduction of ≥20 mmHg from baseline.
Time frame: At 12 weeks (up to 20 weeks)
Change in mean 24-hour diastolic blood pressure
Time frame: Baseline to 12 weeks (up to 20 weeks)
Change in nocturnal systolic and diastolic blood pressure
Time frame: Baseline to 12 weeks (up to 20 weeks)
Change in daytime systolic and diastolic blood pressure
Time frame: Baseline to 12 weeks (up to 20 weeks)
Change in blood pressure variability
Change in variability indices of 24-hour, daytime, and nocturnal blood pressure.
Time frame: Baseline to 12 weeks (up to 20 weeks)
Change in dipping status (dipper/non-dipper proportion)
Time frame: Baseline to 12 weeks (up to 20 weeks)
Dipper conversion rate
Time frame: At 12 weeks (up to 20 weeks)
Change in morning blood pressure surge (MBPS)
Time frame: Baseline to 12 weeks (up to 20 weeks)
Change in pulse pressure
Time frame: Baseline to 12 weeks (up to 20 weeks)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.
Of 81 industry-sponsored observational studies under Hypertension, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 10 months is below that.
Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →